Coherus BioSciences (NASDAQ:CHRS) Announces Earnings Results

Coherus BioSciences (NASDAQ:CHRS) released its earnings results on Monday. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.34), Zacks reports.

Coherus BioSciences Price Performance

NASDAQ CHRS remained flat at $1.04 during trading on Monday. 3,534,134 shares of the company’s stock were exchanged, compared to its average volume of 1,917,392. The company has a 50 day moving average of $1.25 and a 200 day moving average of $1.19. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $2.64. The stock has a market cap of $120.53 million, a price-to-earnings ratio of -13.00 and a beta of 0.92.

Analyst Ratings Changes

A number of research analysts have weighed in on CHRS shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Coherus BioSciences in a research note on Thursday, January 23rd. Robert W. Baird lifted their price objective on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Coherus BioSciences currently has a consensus rating of “Moderate Buy” and an average target price of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.